We are live on ! Find out more
HTGM

HTG Molecular Diagnostics

Delisted

HTGM was delisted on the 14th of June, 2023.

54 hedge funds and large institutions have $67M invested in HTG Molecular Diagnostics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,933% more call options, than puts

Call options by funds: $61K | Put options by funds: $3K

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

23% more funds holding

Funds holding: 44 → 54 (+10)

2.57% less ownership

Funds ownership: 49.25% → 46.69% (-2.6%)

28% less capital inflows, than outflows

Capital inflows: $5.98M | Capital outflows: $8.31M

Holders
54
Holders Change
+10
Holders Change %
+22.73%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
14
Reduced
11
Closed
9
Calls
$61​K
Puts
$3​K
Net Calls
+$58​K
Net Calls Change
+$58​K

HTGM Hedge Fund Activity: Q3 2018 in Review

54 of the 4,393 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics (HTGM) for Q3 2018, worth a combined $67M — up 47% from $45.6M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new HTGM positions and 9 closed out — a net gain of 10 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Russell Investments Group, opening a new position worth an estimated $791K. The largest seller was Stonepine Capital Management, cutting an estimated $4.23M.

  • 54 institutional investors held HTG Molecular Diagnostics (HTGM) as of Q3 2018, up from 44 in Q2 2018.
  • Funds reported $67M of HTG Molecular Diagnostics stock for Q3 2018, up 47% quarter-over-quarter.
  • 19 funds opened new HTG Molecular Diagnostics positions in Q3 2018 and 9 closed out, a net change of +10 holders.
  • The largest HTG Molecular Diagnostics buyer in Q3 2018 was Russell Investments Group, an estimated $791K added.
  • The largest HTG Molecular Diagnostics seller in Q3 2018 was Stonepine Capital Management, an estimated $4.23M sold.

Based on aggregated 13F filings for Q3 2018.